



# **The Next Wave of iBio Innovation**

## **Amylin Receptor**




# Harnessing Amylin Biology with Precision Targeting: iBio's Engineered Antibody Agonist Approach



## Why We Target Amylin

- **Validated metabolic hormone** that promotes satiety, slows gastric emptying, and reduces postprandial glucose excursions
- Clinical studies with amylin analogs confirm efficacy in weight loss, but **peptide-based approaches may be sub-optimal** (dosing, tolerability, manufacturability)<sup>1,2</sup>
- Amylin receptor-selective antibody agonists could provide a differentiated profile, with **potential for longer duration of action and reduced side effects** alone or in combination therapy

*Selective amylin receptor agonists (SARA) (rather than DACRAs\*) have potential as a more precisely targeted obesity intervention*



3. J Gingell, J. et al. An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. *Cell Discov* 2, 16012 (2016).

\*Dual Amylin and Calcitonin Receptor Agonists

